Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 5:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Kineret Clear all
Withdrawn Phase 2 Interventional

Anakinra, COVID-19, Cytokine Storm

NCT04603742
View directory record Official record
Conditions
Covid19, Cytokine Storm, Mechanical Ventilation Complication
Interventions
Anakinra, 0.9% Saline
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Jul 24, 2026, 5:20 AM EDT
Completed Phase 2 Interventional Results available

Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy

NCT04359784
View directory record Official record
Conditions
B-Cell Non-Hodgkin Lymphoma
Interventions
Anakinra, X-Ray Imaging, Positron Emission Tomography, Computed Tomography, Bone Marrow Aspiration, Bone Marrow Biopsy, Lumbar Puncture, Biospecimen Collection
Biological · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Jul 24, 2026, 5:20 AM EDT
Completed Phase 2 Interventional Results available

Trial of Anakinra (Plus Zinc) or Prednisone in Patients With Severe Alcoholic Hepatitis

NCT04072822
View directory record Official record
Conditions
Alcoholic Hepatitis
Interventions
Anakinra and Zinc, Prednisone, Placebos
Drug
Lead sponsor
Indiana University
Other
Eligibility
21 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
10
States / cities
Phoenix, Arizona • Jacksonville, Florida • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Jul 24, 2026, 5:20 AM EDT
Terminated Phase 1 Interventional

Anakinra, A Recombinant Human IL-1 Receptor Antagonist for Neuroinflammation in HIV-1 Infection

NCT02527460
View directory record Official record
Conditions
HIV Infections, Neurologic Disorders
Interventions
Anakinra
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 61 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 28, 2019 · Synced Jul 24, 2026, 5:20 AM EDT
Completed Phase 2 Interventional Results available

Anakinra With or Without Dexamethasone in Treating Patients With Smoldering or Indolent Multiple Myeloma

NCT00635154
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
Anakinra (IL-1Ra), Dexamethasone acetate
Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Jul 24, 2026, 5:20 AM EDT
Terminated Phase 2 Interventional

Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma

NCT04205838
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma, Progressive Disease, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Anakinra, Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine, Fludarabine Phosphate
Biological · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Davis, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jul 24, 2026, 5:20 AM EDT
Completed Phase 1Phase 2 Interventional

Study to Prevent Cartilage Damage Following Acute Knee Injury.

NCT00332254
View directory record Official record
Conditions
Knee Injury
Interventions
Anakinra
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 30 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Jul 24, 2026, 5:20 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Anakinra for the Treatment of Chronically Inflamed White Matter Lesions in Multiple Sclerosis

NCT04025554
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Anakinra
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 120 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Jul 24, 2026, 5:20 AM EDT
Completed Early Phase 1 Interventional

Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic Cancer

NCT02550327
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
Nab-paclitaxel, Gemcitabine, Cisplatin, Anakinra
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Jul 24, 2026, 5:20 AM EDT
Completed Phase 1Phase 2 Interventional

Open-label Study of Anakinra in MPS III

NCT04018755
View directory record Official record
Conditions
Mucopolysaccharidosis III
Interventions
anakinra
Biological
Lead sponsor
Lynda E Polgreen
Other
Eligibility
4 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Jul 24, 2026, 5:20 AM EDT
Terminated Phase 2 Interventional Results available

Treatment of Acute Pericarditis With Anakinra

NCT03224585
View directory record Official record
Conditions
Acute Pericarditis
Interventions
Anakinra, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
12 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 22, 2021 · Synced Jul 24, 2026, 5:20 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Biologic Therapy to Prevent Osteoarthritis After ACL Injury

NCT03968913
View directory record Official record
Conditions
Anterior Cruciate Ligament Injuries
Interventions
Anakinra injection, sterile saline injection
Drug · Procedure
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 35 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Jul 24, 2026, 5:20 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pilot Study of the Safety and Efficacy of Anakinra (Recombinant Human Interleukin-1 Receptor Antagonist) in Heart Failure

NCT01300650
View directory record Official record
Conditions
Heart Failure
Interventions
Anakinra
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 29, 2017 · Synced Jul 24, 2026, 5:20 AM EDT
Completed Phase 2 Interventional Results available

Inflammation in Chronic Kidney Disease and Cardiovascular Disease - The Role of Genetics and Interleukin-1 Receptor Antagonist (IL-1ra)

NCT00897715
View directory record Official record
Conditions
Chronic Kidney Disease, Cardiovascular Disease
Interventions
Rilonacept, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Jul 24, 2026, 5:20 AM EDT
Completed Phase 1Phase 2 Interventional

Dupilumab_Metastatic NSCLC

NCT05013450
View directory record Official record
Conditions
Metastatic Non-small Cell Lung Cancer
Interventions
Dupilumab, PD-1/PD-L1 blockade, Anakinra
Drug
Lead sponsor
Thomas Marron
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 24, 2026, 5:20 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of the Effects of Anakinra in Corticosteroid-resistant Subjects With Sudden Sensorineural Hearing Loss

NCT02414152
View directory record Official record
Conditions
Hearing Loss, Sudden
Interventions
anakinra
Drug
Lead sponsor
Andrea Vambutas
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2017 · Synced Jul 24, 2026, 5:20 AM EDT
Active, not recruiting Phase 2 Interventional

Interleukin-1 Blockade in Acute Myocardial Infarction to Prevent Heart Failure

NCT05177822
View directory record Official record
Conditions
Heart Failure
Interventions
Anakinra, Placebo
Drug · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Charlottesville, Virginia • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 24, 2026, 5:20 AM EDT
Completed Not applicable Interventional Results available

Pilot Feasibility Study of the Safety and Efficacy of Anakinra in Heart Failure With Preserved Ejection Fraction

NCT01542502
View directory record Official record
Conditions
Heart Failure
Interventions
Anakinra, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 5, 2017 · Synced Jul 24, 2026, 5:20 AM EDT
Not yet recruiting Phase 3 Interventional

COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE"

NCT07281027
View directory record Official record
Conditions
New Onset Refractory Status Epilepticus, New-Onset Refractory Status Epilepticus, Febrile Infection-Related Epilepsy Syndrome (FIRES)
Interventions
Anakinra, Tocilizumab, Standard medical treatment
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
2 Years and older
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
25
States / cities
Phoenix, Arizona • Aurora, Colorado • New Haven, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jul 24, 2026, 5:20 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

NCT04150913
View directory record Official record
Conditions
Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma, Neurotoxicity, Neurotoxicity Syndromes, Cytokine Release Syndrome
Interventions
Anakinra, Axicabtagene Ciloleucel
Drug
Lead sponsor
Marcela V. Maus, M.D.,Ph.D.
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Jul 24, 2026, 5:20 AM EDT
Completed Phase 2 Interventional Results available

Anakinra for Inflammatory Pustular Skin Diseases

NCT01794117
View directory record Official record
Conditions
Sneddon-Wilkinson, Acrodermatitis Continua of Hallopeau, Pustular Psoriasis, Palmoplantar Pustulosis
Interventions
Anakinra
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 110 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2021 · Synced Jul 24, 2026, 5:20 AM EDT
Recruiting Phase 2 Interventional

Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)

NCT04926467
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
Anakinra
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Jul 24, 2026, 5:20 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy

NCT04148430
View directory record Official record
Conditions
B Cell ALL, B-Cell Lymphoma, B-cell Non Hodgkin Lymphoma
Interventions
Anakinra
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
Hackensack, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Jul 24, 2026, 5:20 AM EDT
Completed Phase 1 Interventional

Anakinra in Treating Patients With Metastatic Cancer Expressing the Interleukin-1 Gene

NCT00072111
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
anakinra
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Jul 24, 2026, 5:20 AM EDT